ライフサイエンスコーパス: arthritis

1 flammations of various origins (colitis from arthritis).

2 es also modulates the course and severity of arthritis.

3 n joint tissue from patients with rheumatoid arthritis.

4 lasts promotes inflammation in murine immune arthritis.

5 artilage integrity in mice with inflammatory arthritis.

6 as the interleukin-27 pathway in rheumatoid arthritis.

7 ew-onset and chronic autoimmune inflammatory arthritis.

8 in regulatory T cells restrains inflammatory arthritis.

9 653048, a compound active against rheumatoid arthritis.

10 in the pathogenesis of autoantibody-induced arthritis.

11 tory bowel disease, sepsis, and inflammatory arthritis.

12 ng interventions in patients with rheumatoid arthritis.

13 n myeloid cells, which modulate inflammatory arthritis.

14 expanded during the immune-priming phase of arthritis.

15 a blocker currently used to treat rheumatoid arthritis.

16 reduced intestinal Th17 cells and attenuated arthritis.

17 hat it is a new target for the inhibition of arthritis.

18 in the systemic sites, leading to augmented arthritis.

19 nd are protected in 2 models of inflammatory arthritis.

20 owel disease, Crohn's disease and rheumatoid arthritis.

21 investigation for the treatment of psoriatic arthritis.

22 ined the role of KKS in autoantibody-induced arthritis.

23 for the treatment of JIA and other types of arthritis.

24 ooperation in the pathogenesis of autoimmune arthritis.

25 algesia and inflammation in collagen-induced arthritis.

26 treated with infliximab after development of arthritis.

27 toimmune diseases, particularly inflammatory arthritis.

28 any diseases like cancer, atherosclerosis or arthritis.

29 er IL-6 blockade in patients with rheumatoid arthritis.

30 lone phosphate (PLP-LCL) in a mouse model of arthritis.

31 ls is highly correlated with the severity of arthritis.

32 effective cell-free therapy for inflammatory arthritis.

33 netrate the blood-brain barrier and prevents arthritis.

34 cal use for indications including rheumatoid arthritis.

35 systemic lupus erythematosus and rheumatoid arthritis.

36 s significantly reduced by SzV-1287 in K/BxN-arthritis.

37 nerative disease enhances the development of arthritis.

38 sis and treatment evaluation of inflammatory arthritis.

39 ells in synovium of patients with rheumatoid arthritis.

40 study the importance of LAIR-1 in autoimmune arthritis.

41 the contribution of type I IFN genes to Lyme arthritis.

42 e brain are highly susceptible to developing arthritis.

43 rne alphavirus that causes acute and chronic arthritis.

44 thritis, and mouse collagen antibody-induced arthritis.

45 egulation as a central problem in rheumatoid arthritis.

46 gGs can be used as biomarkers for rheumatoid arthritis.

47 ed with the inflammatory state of rheumatoid arthritis.

48 as inflammatory bowel disease and rheumatoid arthritis.

49 atorvastatin and pravastatin in inflammatory arthritis.

50 s (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), a

51 Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]), and syst

52 roke ($4,325; 95% CI, $2,687 to $5,964), and arthritis ($3,534; 95% CI, $2,475 to $4,593).

53 mbined lots, 20.4% high-dose, 3.0% placebo), arthritis (5.1% combined lots, 4.2% high-dose, 0.0% plac

54 t for hyperlipidemia (68%; kappa = 0.36) and arthritis (66%; kappa = 0.14).

55 n joint tissue from patients with rheumatoid arthritis, a chronic immune-mediated arthritis that affe

56 fidence interval [CI] = 1.2-2.5), rheumatoid arthritis (adjusted OR = 1.7; 95% CI = 1.5-1.9), type 1

57 cipants were patients with active rheumatoid arthritis aged at least 18 years, with four or more of 6

58 Antigen-induced arthritis (AIA) and K/BxN serum transfer-induced arthrit

59 cell therapy in an antigen-induced model of arthritis (AIA).

60 the group with mild psoriasis with psoriatic arthritis also had an increased risk of incident uveitis

61 titis and cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, pulmonary disease, pre-t

62 Five children with uveitis and psoriatic arthritis and 1 with uveitis and psoriasis Observational

63 A number of human diseases, such as arthritis and atherosclerosis, include characteristic pa

64 lamed synovium from patients with rheumatoid arthritis and compared with synovium from healthy donors

65 Variants in GDF5 are associated with human arthritis and decreased height, but the causal mutations

66 Surveillance was enhanced for arthritis and dermatitis through to day 56.

67 epididymo-orchitis, proctitis, and reactive arthritis and facilitates human immunodeficiency virus t

68 g in various common diseases such as cancer, arthritis and fibrosis.

69 stigations and clinical trials in rheumatoid arthritis and follicular lymphoma.

70 type II collagen they developed more severe arthritis and had a greater percentage of affected limbs

71 eflex to significantly ameliorate rheumatoid arthritis and inflammatory bowel disease provide a path

72 as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), metabolic dis

73 resulted in increased osteoclastogenesis in arthritis and inflammatory osteolysis models.

74 cient mice are resistant to collagen-induced arthritis and interaction of DCs and T cells from these

75 We investigated the relationship between arthritis and mental health (depression spectrum, psycho

76 Integrated interventions addressing arthritis and mental health comorbidities are warranted

77 eting may be a safe therapeutic strategy for arthritis and other inflammatory conditions, particularl

78 well as classic inflammatory diseases (e.g., arthritis and periodontal diseases).

79 Ablation of DJ-1 in mouse models of arthritis and RANKL-induced bone disease leads to an inc

80 t contribute to the enhancement of asthma or arthritis and seemed to be due to alterations during mas

81 CD4(+) T cells from patients with rheumatoid arthritis and systemic lupus erythematosus were demethyl

82 roup with severe psoriasis without psoriatic arthritis and the group with mild psoriasis with psoriat

83 icantly reduced severity of collagen-induced arthritis and this was accompanied by a significant redu

84 mmunized with type II collagen/CFA to induce arthritis and were treated with either the stimulatory m

85 d symptoms of patients with active psoriatic arthritis and who had previously inadequate response to

86 , obesity, metabolic syndrome, diabetes, and arthritis) and increased all-cause mortality (incidence

87 roke, emphysema, high cholesterol, diabetes, arthritis, and asthma) and multiple chronic conditions (

88 rogression of multiple sclerosis, rheumatoid arthritis, and breast cancer.

89 including age-related macular degeneration, arthritis, and cancer.

90 on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorders (interfer

91 ine lines: KitWsh/Wsh, which develops robust arthritis, and KitW/Wv, which does not.

92 rse activities against cancer, inflammation, arthritis, and lupus in vivo.

93 ted in Ag-induced arthritis, zymosan-induced arthritis, and methylated BSA/IL-1 arthritis by both pro

94 olyarthritis: rat and mouse collagen-induced arthritis, and mouse collagen antibody-induced arthritis

95 Osteomyelitis, arthritis, and musculoskeletal inflammation are common f

96 intestinal microbiota perturbations precede arthritis, and that modulation of the intestinal microbi

97 a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

98 75; neck pain: aOR, 1.22; 95% CI, 1.07-1.39; arthritis: aOR, 1.56; 95% CI, 1.40-1.73; and centralized

99 Inflammatory diseases such as arthritis are chronic conditions that fail to resolve sp

100 ti-inflammatory drugs (NSAIDs) when used for arthritis are difficult to conduct and even more challen

101 he cytokine and cellular pathways triggering arthritis are well defined, those responsible for the re

102 nificant efficacy in the rat antigen induced arthritis as well as in the hyperalgesia and angiogenesi

103 trait locus underlying Borrelia burgdorferi arthritis-associated locus 1 (Bbaa1).

104 ocular hypotony (OH) in juvenile idiopathic arthritis-associated uveitis (JIAU).

105 Many cases of juvenile idiopathic arthritis-associated uveitis, many cases of intermediate

106 This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary diseases a

107 on, heart disease, high cholesterol, stroke, arthritis, asthma, chronic obstructive pulmonary disease

108 y stronger among the poorest individuals for arthritis, asthma, diabetes, edentulism, and >/=4 chroni

109 pulation and not necessarily associated with arthritis, at least before the advent of modern rheumato

110 s may provide insight into why patients with arthritis being treated with IL-6 inhibitors develop new

111 trol positional disease patterns not only in arthritis but in any disease with a prominent stromal co

112 3 is specific in regulating adjuvant-induced arthritis but not antigen-induced autoimmunity, and with

113 ence vascular and cellular mechanisms in CFA-arthritis, but significantly decreased histopathological

114 n-induced arthritis, and methylated BSA/IL-1 arthritis by both prophylactic and therapeutic anti-G-CS

115 5 expression in macrophages enhances chronic arthritis by conferring apoptotic resistance to activate

116 17 to promote the pathogenesis of autoimmune arthritis by cooperating with IL-17 to induce inflammato

117 nd specifically the development of psoriatic arthritis by impeding the Adam17-mediated release of TNF

118 diated anti-inflammation in collagen-induced arthritis by using PGRN and IL-10 genetically modified m

119 ctivity can result in many diseases, such as arthritis, cardiovascular diseases, neurological disorde

120 In an in vivo model of inflammatory arthritis, cartilage integrity was determined histologic

121 rohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and multiple scler

122 The collagen-induced arthritis (CIA) model and DR-1 transgenic mice were used

123 In the collagen-induced arthritis (CIA) model, while ectopic expression of FGF2

124 ect of engineered MSCs in a collagen-induced arthritis (CIA) model.

125 rthritis progression in the collagen-induced arthritis (CIA) mouse model to an extent just shy of dis

126 Collagen-induced arthritis (CIA) was induced in male DBA/1J mice.

127 Upon induction of collagen-induced arthritis (CIA), tau-tg mice displayed an increased inci

128 in the preclinical phase of collagen induced arthritis (CIA).

129 The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) trial found tr

130 nstructed for 213 AS cases and 46 rheumatoid arthritis controls using family data.

131 ith added attention to signs and symptoms of arthritis, depression, and anxiety.

132 ged 18 years or older with active rheumatoid arthritis despite methotrexate therapy.

133 revealed a unique role for IFN-beta in Lyme arthritis development in B6.C3-Bbaa1 mice.

134 iquely upregulated in association with Bbaa1 arthritis development, and myostatin expression was link

135 rity of various illnesses such as rheumatoid arthritis, diabetes, and liver diseases.

136 eriodontal disease, presence of inflammatory arthritis does not appear to be one of them.

137 pressed at the plasma membrane of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs) isolate

138 rin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes.

139 soriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalgia) than those with NWU or LWU.

140 lder, had a confirmed diagnosis of psoriatic arthritis for at least 6 months, and had a previous inad

141 e group with severe psoriasis with psoriatic arthritis had the greatest risk of incident uveitis comp

142 Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P1

143 tion and is therapeutic against inflammatory arthritis; however, the underlying immunological mechani

144 n criteria were (i) patients with rheumatoid arthritis, (ii) adult population age >/=16years, (iii) n

145 ing differential sensitivity to IgG-mediated arthritis in 2 mast cell-deficient murine lines: KitWsh/

146 icacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

147 pared to expected age of onset for psoriatic arthritis in childhood).

148 The more severe pathogenesis of psoriatic arthritis in Fhl2 knockout mice coincided with enhanced

149 240 reduces the severity of collagen-induced arthritis in mice and crescentic glomerulonephritis in r

150 e used IL-23 in vivo gene transfer to induce arthritis in mice and showed that elevated serum LTB4 an

151 tibiotics or germ-free condition can prevent arthritis in mice.

152 ow that DEK is crucial to the development of arthritis in mouse models, thus making it an appropriate

153 Gout is a common type of inflammatory arthritis in patients seen by primary care physicians.

154 nce and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery (gast

155 methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate respons

156 Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9(+)

157 ibition of myostatin in vivo suppressed Lyme arthritis in the reduced interval Bbaa1 congenic mice, f

158 set ameliorated the severity of inflammatory arthritis including arthritis indices, paw thickness, ca

159 Having arthritis increased the odds of subclinical psychosis (O

160 prevalence of neurodegenerative disease and arthritis increases with age.

161 he Western Ontario and McMaster Universities Arthritis Index Scale (P = .78, I2 = 65%).

162 severity of inflammatory arthritis including arthritis indices, paw thickness, cartilage damage and n

163 e Freund's adjuvant, with similar effects in arthritis induced by several oil adjuvants (hexadecane,

164 eases, including allergy, diabetes, obesity, arthritis, inflammatory bowel diseases, and even neurops

165 to provide a therapeutic role in rheumatoid arthritis, inflammatory intestinal disease, colitis-asso

166 Rheumatoid arthritis is a chronic autoimmune disease that causes pr

167 Rheumatoid arthritis is a chronic autoimmune disorder resulting in

168 Rheumatoid arthritis is an autoimmune disorder that affects the joi

169 Rheumatoid arthritis is an inflammatory condition characterized by

170 n B6.C3-Bbaa1 and C57BL/6 mice revealed that arthritis is initiated by radiation-sensitive cells, but

171 Juvenile idiopathic arthritis (JIA) is a wide group of diseases, characteriz

172 biosensor for detecting juvenile idiopathic arthritis (JIA) was developed based on the immobilizatio

173 he polyarticular form of juvenile idiopathic arthritis (JIA), using 2 independent cohorts to ascertai

174 tive in the treatment of juvenile idiopathic arthritis (JIA).

175 s milk allergy (CMA) and juvenile idiopathic arthritis (JIA).

176 patients with erythema migrans (EM) or Lyme arthritis (LA) to elucidate their role early and late in

177 ent diagnostic tests applied to inflammatory arthritis lack the necessary specificity to appropriatel

178 the intestinal microbiota after the onset of arthritis may offer therapeutic opportunities.

179 uveitis that accompanies juvenile psoriatic arthritis might be a distinct disease that is particular

180 ndogenous IL-1R2 in the K/BxN serum transfer arthritis model and in IL-1beta- or LPS-induced systemic

181 A new G-CSF-driven (methylated BSA/G-CSF) arthritis model was established enabling us to demonstra

182 Using the K/BxN autoimmune arthritis model, we elucidate a novel mechanism whereby

183 Using an autoimmune arthritis model, we show that a constituent of the gut m

184 model and the delayed-type hypersensitivity arthritis model.

185 flammatory bowel disease and an inflammatory arthritis model.

186 ghly efficacious in a mouse collagen-induced arthritis model.

187 gene PUMA, has therapeutic efficacy in a rat arthritis model.

188 mmation as shown in the K/BxN serum transfer arthritis model.

189 on and bone destruction in the serum-induced arthritis model.

190 In both arthritis models clinical (joint swelling) and histologi

191 sic and anti-inflammatory actions in chronic arthritis models of distinct mechanisms, without inducin

192 in the CIA and delayed-type hypersensitivity arthritis models.

193 us anaphylaxis, ovalbumin-induced asthma and arthritis models.

194 on of peripheral TNF-alpha in the context of arthritis modulates the amyloid phenotype by regulating

195 a mouse model for studying Brucella-induced arthritis, musculoskeletal complications, and systemic r

196 pidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression,

197 receptor antagonist used to treat rheumatoid arthritis, normalizes hippocampal neurotransmission and

198 Self-limited, post-vaccination arthritis occurred in 4.5% (19 of 418) of vaccinees (med

199 these alterations precede the development of arthritis or are rather a consequence of disease.

200 d in adjuvant oils, such as collagen-induced arthritis or experimental autoimmune encephalomyelitis.

201 uveitis that accompanies juvenile psoriatic arthritis or psoriasis.

202 = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

203 incident (new-onset) psoriasis or psoriatic arthritis, or progression to severe psoriasis.

204 high cholesterol: OR 1.26; stroke: OR 1.99; arthritis; OR 1.71; asthma: OR 1.56; chronic obstructive

205 mplant-related infection comprised of septic arthritis, osteomyelitis, and biofilm formation on the i

206 fective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nursing interve

207 , while DCs from CTLA4-Ig-treated rheumatoid arthritis patients displayed diminished LC3B transcripts

208 ts with synovial fluid cells from rheumatoid arthritis patients reduced inflammatory cytokine product

209 events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosis factor-al

210 ssed in macrophages isolated from rheumatoid-arthritis patients, revealing a disease-associated signa

211 neutralizes mouse uPA significantly reduced arthritis progression in the CIA and delayed-type hypers

212 ase-type plasminogen activator (uPA) reduces arthritis progression in the collagen-induced arthritis

213 replacement, terminal illness, inflammatory arthritis, prosthetic leg, cognitive impairment, lack of

214 liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).

215 hritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chronic inflamm

216 nditions such as atherosclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

217 nt attitude/perception of ability to control arthritis, quality of life, health utility, health care

218 From 277 patients with rheumatoid arthritis (RA) and 141 healthy individuals, we also iden

219 ogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD.

220 ation of periodontal disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

221 nt of autoimmune diseases such as rheumatoid arthritis (RA) and is associated with the expression of

222 vation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete.

223 Current treatments for rheumatoid arthritis (RA) do not reverse underlying aberrant immune

224 genic T cells in individuals with rheumatoid arthritis (RA) infiltrate non-lymphoid tissue sites, man

225 ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory condition assoc

226 KEY POINTS: Rheumatoid arthritis (RA) is a chronic inflammatory condition assoc

227 Rheumatoid arthritis (RA) is a progressive disease that affects bot

228 sed risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic heart disease

229 The development of rheumatoid arthritis (RA) is linked to functional changes in synovi

230 Rheumatoid arthritis (RA) is the most common inflammatory arthropat

231 inant human TRAIL in experimental rheumatoid arthritis (RA) models.

232 hy donors (HDs) and patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

233 Rheumatoid arthritis (RA) patients have been observed to be at a lo

234 led synovial fluid (SF) from four rheumatoid arthritis (RA) patients.

235 this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.

236 Recent metabolomics studies of Rheumatoid Arthritis (RA) reported few metabolites that were associ

237 ical improvement in patients with rheumatoid arthritis (RA), and macrophages are reduced in synovial

238 In rheumatoid arthritis (RA), cartilage and bone matrix are degraded,

239 In rheumatoid arthritis (RA), chronic inflammation is thought to drive

240 red epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic-citrullina

241 Disease activity of rheumatoid arthritis (RA), evaluated as Disease Activity Score (DAS

242 In rheumatoid arthritis (RA), immunological triggers at mucosal sites,

243 for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthriti

244 implicated in the pathogenesis of rheumatoid arthritis (RA).

245 ), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).

246 nt in two-thirds of patients with rheumatoid arthritis (RA).

247 ted inflammatory signaling in the rheumatoid arthritis (RA).

248 nance of autoimmune diseases like rheumatoid arthritis (RA).

249 hotrexate in patients with active rheumatoid arthritis (RA).

250 e osteoclastogenic role of H4R in rheumatoid arthritis (RA).

251 flammatory cytokine implicated in rheumatoid arthritis (RA).

252 farming has been associated with rheumatoid arthritis (RA); pesticides may account for this associat

253 bjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244).

254 In the adjuvant-induced arthritis rat model, CHMFL-BTK-11 ameliorated the inflam

255 omplications are a major cause of rheumatoid arthritis-related mortality.

256 tantial number of patients with inflammatory arthritis remain resistant to current therapies, and eve

257 beneficial actions of statins in rheumatoid arthritis remains of interest.

258 en KitW/Wv and KitWsh/Wsh mice revealed that arthritis resistance reflects a hematopoietic defect in

259 c biomarkers specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthriti

260 ercentage injected dose) correlated with the arthritis score (Spearman rho, 0.77; P < 0.0001).

261 In contrast, macroscopic arthritis scores had increased up to 600% in untreated m

262 s quantified and correlated with macroscopic arthritis scores.

263 might be more sensitive than the macroscopic arthritis scoring method.

264 ange (overall, pain, and functional status), arthritis self-efficacy, coping, and pain catastrophizin

265 Inhibition of Kal ameliorated arthritis severity and incidence at early stage STIA and

266 IL-1R2 deficiency aggravated arthritis severity and increased mRNA levels for key cyt

267 Because DNA fragments can increase arthritis severity in preclinical models, we then explor

268 When applied to systemic juvenile idiopathic arthritis (sJIA), an autoinflammatory disease of unknown

269 the intestinal microbiota during established arthritis specifically reduced intestinal Th17 cells and

270 ritis (AIA) and K/BxN serum transfer-induced arthritis (STIA) were induced in both chGRKO mice and th

271 Arthritis subsided more efficiently in CIA mice injected

272 ency of a GDF5 haplotype that also increases arthritis susceptibility in many human populations.

273 t not IL-1-deficient megakaryocytes restored arthritis susceptibility to KitW/Wv mice.

274 and transfer of WT platelets did not restore arthritis susceptibility.

275 rs: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytop

276 umatoid arthritis, a chronic immune-mediated arthritis that affects up to 1% of the population.

277 e we show using the antigen-induced model of arthritis that the degree of DNA methylation within AC c

278 In inflammatory arthritis, the dysregulation of osteoclast activity by p

279 y of several systemic diseases, ranging from arthritis to neurodegenerative diseases.

280 umab is approved for psoriasis and psoriatic arthritis treatment and has been successfully evaluated

281 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comp

282 ein Ab-positive arthralgia, undifferentiated arthritis (UA), early RA, and established RA cohorts in

283 AK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.

284 atin (0.2 mg/kg)-to mice during inflammatory arthritis up-regulated systemic and tissue amounts of a

285 activation state of macrophages and promotes arthritis via differentially regulating cyclooxygenase-2

286 Arthritis was assessed by measurement of joint swelling

287 estoration of susceptibility to IgG-mediated arthritis was neutrophil independent but required IL-1 a

288 Adjusted HRs of psoriatic arthritis were 0.29 (95% CI, 0.12-0.71) and 0.53 (95% CI

289 People with arthritis were at increased odds of subsyndromal depress

290 mproved prognosis of psoriasis and psoriatic arthritis, whereas gastric banding was not.

291 ial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhi

292 lacebo at month 3 in patients with psoriatic arthritis who had previously had an inadequate response

293 ofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to c

294 old white woman with a history of rheumatoid arthritis who was taking glucocorticoids and methotrexat

295 RETATION: In patients with active rheumatoid arthritis who were refractory or intolerant to anti-TNF

296 tory T (Treg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone

297 pe in MHC-III was linked to the induction of arthritis with incomplete Freund's adjuvant, with simila

298 ed studies investigating the relationship of arthritis with mental health outcomes are lacking, parti

299 ritical role for Kal in autoantibody-induced arthritis with pleiotropic effects, which suggests that

300 n and disease were ameliorated in Ag-induced arthritis, zymosan-induced arthritis, and methylated BSA